Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Archived from the original on October 30, 2001
Retatrutide remains investigational, with Phase 3 trials ongoing and potential approval not expected until mid-2026 or 2027 at the earliest
* Chemical structures of neuroendocrine hormones (cortisol, testosterone, estradiol, and epinephrine), neurotransmitters (dopamine, norepinephrine, epinephrine, and its precursor tyrosine), and plant metabolites of adaptogenic plants tyrosol, salidroside, rosavin, eleutherosides, acteoside, schizandrins, ginsenoside Rg5, withanolide A, withaferin A, andrographolide, acteoside, 20-hydroxyecdysone, tanshinones, bacosides, bacoposodes, lancemasides, tangshenoside VIII codonoside B, salvianolic acids, p-coumaric, ferulic, synapic acids, and cucurbitacin R diglucoside